Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders
TL;DR: The design and evolution of this innovative device from a laboratory concept model and the challenges that were overcome during its development and scaleup to mass production are described.
read more
Abstract: The Respimat(®) Soft Mist™ Inhaler (SMI) (Boehringer Ingelheim International GmbH, Ingelheim, Germany) was developed in response to the need for a pocket-sized device that can generate a single-breath, inhalable aerosol from a drug solution using a patient-independent, reproducible, and environmentally friendly energy supply. This paper describes the design and evolution of this innovative device from a laboratory concept model and the challenges that were overcome during its development and scaleup to mass production. A key technical breakthrough was the uniblock, a component combining filters and nozzles and made of silicon and glass, through which drug solution is forced using mechanical power. This allows two converging jets of solution to collide at a controlled angle, generating a fine aerosol of inhalable droplets. The mechanical energy comes from a spring which is tensioned by twisting the base of the device before use. Additional features of the Respimat(®) SMI include a dose indicator and a lockout mechanism to avoid the problems of tailing-off of dose size seen with pressurized metered dose inhalers. The Respimat(®) SMI aerosol cloud has a unique range of technical properties. The high fine particle fraction allied with the low velocity and long generation time of the aerosol translate into a higher fraction of the emitted dose being deposited in the lungs compared with aerosols from pressurized metered dose inhalers and dry powder inhalers. These advantages are realized in clinical trials in adults and children with obstructive lung diseases, which have shown that the efficacy and safety of a pressurized metered dose inhaler formulation of a combination bronchodilator can be matched by a Respimat(®) SMI formulation containing only one half or one quarter of the dose delivered by a pressurized metered dose inhaler. Patient satisfaction with the Respimat(®) SMI is high, and the long duration of the spray is of potential benefit to patients who have difficulty in coordinating inhalation with drug release.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Inhalation drug delivery devices: technology update
TL;DR: This review summarizes the structural and mechanical features of aerosol delivery devices with respect to mechanisms of aerosoli generation, their use with different formulations, and their advantages and limitations.
Optimizing drug delivery in COPD: The role of inhaler devices
Paola Rogliani,Luigino Calzetta,Angelo Coppola,Francesco Cavalli,Josuel Ora,Ermanno Puxeddu,Maria Gabriella Matera,Mario Cazzola +7 more
TL;DR: A review of the literature on different inhaler device requirements indicates the availability of robust data on the devices characteristics and factors influencing selection of delivery devices is limited.
177
Montreal Protocol on Substances that Deplete the Ozone Layer
R. Quentin Grafton,Harry W. Nelson,N. Ross Lambie,Paul R. Wyrwoll +3 more
- 01 Jan 2012
TL;DR: In paragraph 13 of decision XX/20 of the Twentieth Meeting of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, the parties requested the Secretariat to inform the Open-ended Working Group about all sources of income received, including the reserves, fund balance and interest, and to provide an indicative report on all expenditures against the agreed budget lines.
174
Choosing the right inhaler for your asthma or COPD patient.
TL;DR: Appropriate selection and correct use of inhalation devices is an integral component in the management of asthma and chronic obstructive pulmonary disease and education and support is crucial, not only to enable patients to recognize the need for optimal disease management, but also to help them develop good inhaler technique.
Aerosol Delivery Devices for Obstructive Lung Diseases.
Roy A. Pleasants,Dean R. Hess +1 more
TL;DR: Aerosol science is evolving, with methods of measurement that include radio-scintigraphy and magnetic resonance imaging, to provide a better understanding of aerosol delivery and effects.
88
References
•Book
Respiratory Drug Delivery
Peter R. Byron
- 27 Dec 1989
TL;DR: The focus of this book is on subjects related to drug delivery to the lung and the chapters consider toxicology from the point of view of drugs and pharmaceutical excipients used in aerosols.
494
•Journal Article
Problems patients have using pressurized aerosol inhalers.
TL;DR: One hundred and thirty-five patients already being treated with drugs by inhalation were found to have a poor inhaler technique, even though most had received instruction on how to use a pressurized aerosol and were considered to be able to use one of these devices correctly.
404
Handbook for the Montreal Protocol on Substances that Deplete the Ozone Layer.
Onu Environnement
- 01 Jan 2009
TL;DR: This eighth edition of the Handbook incorporates the full text of the treaty and an updated list of all decisions adopted by the Meeting of the Parties to the Montreal Protocol (covering policy, legal, non-compliance, science and technology, and other technical issues associated with the implementation of and compliance with the Protocol), along with other relevant information up to 2008.
372
•Journal Article
How should a pressurized beta-adrenergic bronchodilator be inhaled?
TL;DR: The evidence for the most effective mode or modes of inhalation of pressurized aerosol bronchodilators is reviewed and the applicability of these simple rules to other types of bronchidilator and to all patients, irrespective of their diagnosis or degree of airway obstruction is considered.
239